Developer docs
API playgroundTry for free, no card

Search company profiles

Curida

Full company profile

uuid000cmf9

Namestring
Curida
Legal namestring
Curida AS
Websiteurl
curida.no
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Curida AS is a Norway-based pharmaceutical contract development and manufacturing organization (CDMO) specializing in sterile and non-sterile liquid formulations, with core competence in Blow-Fill-Seal (BFS) and nasal spray manufacturing. The company operates three GMP-certified sites in Norway — Elverum (the flagship BFS and nasal spray facility with 6 BFS lines and 4 nasal spray lines producing ~255 million units annually), Fornebu (biologics centre of excellence for monoclonal antibody manufacturing, formerly Diatec), and Ås (small-scale pharmacy formulations, cosmetics and nutrition, formerly Ås Produksjonslab). Founded in 2015 from a 1974-vintage Elverum plant revived by employees, Curida has grown via the 2017 Ås Produksjonslab acquisition and 2019 Diatec Monoclonals acquisition, consolidating three legacy business units under a unified CDMO brand in September 2025.

Curida sells end-to-end CDMO services — formulation, technology transfer (200+ SKUs completed to date under ISPE Good Practice Guide/PMI methodology), fill-finish across BFS, nasal spray, and liquid bottles (glass, LDPE, PET), controlled-drugs manufacturing (including morphine, fentanyl, and cannabis-based medicines), and analytical/microbiological testing — to pharmaceutical, biotech, and diagnostic customers across Europe and globally. The biologics franchise offers monoclonal antibody development, mammalian cell banking using 3L and 50L stirred-tank bioreactors, purification, and bioconjugation (10+ conjugation types) for IVD and clinical supply, serving 40+ diagnostic partners. In October 2025 the company announced a strategic partnership with Rommelag to install Europe's first BFS bottelpack 550 line, adding next-generation capacity and a sustainability-flexible platform to the sterile portfolio.

Curida's revenue model is B2B contract manufacturing services priced by project (formulation, tech transfer, fill-finish, commercial supply), with the customer base spanning academia and start-ups through to Big Pharma, and finished products exported to 80+ countries. Ownership is private and institutional: Signet Healthcare Partners (a US healthcare PE firm) led a 230M-260M NOK growth investment in April 2024 alongside existing Norwegian shareholders Canica, Investinor, Klaveness Marine, and Farvatn Private Equity. The company holds EU GMP, ISO 13485:2016, ISO 9001:2015 certifications, and in February 2026 earned an EcoVadis Bronze Award with a 17-point sustainability score improvement. Financial details, including revenue, are not publicly disclosed.

Short descriptiontext

Curida is a Norwegian pharmaceutical CDMO specializing in Blow-Fill-Seal, nasal spray, and biologics contract manufacturing for pharmaceutical, biotech, and diagnostic clients across Europe and 80+ countries. It operates three GMP-certified sites delivering fill-finish, tech transfer, and commercial supply services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersElverum, Norway
HQ citystring
Elverum
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, blow-fill-seal technology, biologics manufacturing services, nasal spray manufacturing, sterile fill-finish
Industry3 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Curida generates revenue through contract manufacturing services for pharmaceutical and biotech companies, providing end-to-end development and manufacturing of liquid pharmaceuticals, biologics, and diagnostic products. Services include formulation, tech transfer, fill-finish, and commercial scale-up under GMP conditions.

curida.no
2Pharmacy Formulations Manufacturing
TypeProfessional Services
Description

Small-scale manufacturing of pharmaceuticals, cosmetics, and nutrition products for Norwegian pharmacies and clients, including unlicensed pharmaceuticals and compounded products.

curida.no
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Curida Biologics
Description

Biologics center of excellence at Technopolis, Fornebu, focusing on monoclonal antibody manufacturing for diagnostics and clinical supply.

curida.no
+1 more record
Core offering1 text field

Curida is a Norwegian pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and contract manufacturing of sterile and non-sterile liquid pharmaceuticals, biologics, and diagnostic products. The company specializes in Blow-Fill-Seal (BFS) and nasal spray manufacturing technologies, delivering services spanning formulation development, tech transfer, fill-finish, analytical testing, and commercial-scale GMP production from facilities in Elverum, Fornebu, and Ås, Norway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 200+ successful SKU tech transfers completed
+3 more records
Product overview1 text field

Curida is an integrated European CDMO offering end-to-end development and contract manufacturing of biologics and sterile or non-sterile liquid pharmaceuticals. The portfolio centers on three core service areas: Nasal & Ophthalmic Solutions (liquid formulations manufacturing using Blow-Fill-Seal and nasal spray technologies for uni-dose and multi-dose formats), Biologics & Diagnostic Solutions (monoclonal antibody development, manufacturing, and bioconjugation services), and Pharmacy Formulations (small-scale manufacturing for Norwegian pharmacies). Supporting these services are four technology platforms: Blow-Fill-Seal Technology, Nasal Spray Manufacturing, Liquid Bottles & Delivery Systems, and Uni-dose & Multi-dose Formats. A strategic partnership with Rommelag brings Europe's first BFS 550 bottelpack system. The company operates GMP-certified sites across Norway (Elverum, Fornebu, Ås) and serves pharmaceutical and diagnostic partners globally, exporting to over 80 countries.

Product and service10 records
1Nasal & Ophthalmic Solutions
CategoryCDMO Service
2Biologics & Diagnostic Solutions
CategoryCDMO Service
3Pharmacy Formulations
CategoryCDMO Service
4Tech Transfer Services
CategoryCDMO Service
5Controlled Drugs Manufacturing
CategorySpecialized CDMO Service
6Bioconjugation Services
CategorySpecialized CDMO Service
7Analytical & Laboratory Services
CategoryCDMO Service
8Blow-Fill-Seal Manufacturing Technology
CategoryManufacturing Technology Platform
9Nasal Spray Manufacturing Technology
CategoryManufacturing Technology Platform
10Nasal Sprays & Suspensions
CategorySpecialized CDMO Service
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-01
Description

Partnership with AFRY to modernize Curida's quality management systems. AFRY implemented a connected, digital eQMS that improves visibility, strengthens data integrity, and supports faster, more informed decision-making for scalable and agile quality foundation.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-01
Description

Strategic partnership with Rommelag, the global leader in Blow-Fill-Seal technology. Curida will become the first company in Europe to install Rommelag's BFS bottelpack 550 system - a next-generation platform designed to deliver greater flexibility, higher output, and enhanced sustainability in sterile liquid manufacturing. The partnership strengthens Curida's position as a European CDMO leader in Nasal & Ophthalmic solutions.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French-headquartered CDMO specializing in Blow-Fill-Seal sterile single-dose liquid manufacturing for ophthalmic, nasal, and respiratory applications. Most direct comparable to Curida in BFS technology focus, end markets, and customer profile.

2Recipharm (Kindeva)
TypeDirect peer
Description

European CDMO with significant sterile fill-finish and Blow-Fill-Seal capabilities serving pharma and biotech customers. Comparable to Curida in CDMO services, geographic base in Europe, and focus on liquid and semi-solid dosage forms.

TypeDirect peer
Description

Former 3M Drug Delivery Systems business, now an independent CDMO specializing in inhalation, transdermal, and Blow-Fill-Seal manufacturing. Closely comparable to Curida in BFS expertise and pharmaceutical drug-delivery focus.

TypeBroad incumbent
Description

Large global CDMO offering sterile fill-finish, nasal spray, and biologics manufacturing across a broad portfolio. While much larger and broader in scope, Catalent overlaps directly with Curida in nasal spray and aseptic fill-finish CDMO services.

TypeBroad incumbent
Description

European-headquartered CDMO with capabilities in solid, semi-solid, and liquid dosage forms including sterile manufacturing. Comparable to Curida as a European CDMO serving pharma customers with contract manufacturing services.

TypeBroad incumbent
Description

German-headquartered CDMO specializing in sterile aseptic fill-finish of injectables and other complex liquid formulations. Comparable to Curida in sterile fill-finish focus, European base, and GMP-certified pharma CDMO positioning.

TypeDirect peer
Description

Global leader in drug delivery systems including nasal spray pumps, closures, and dispensing components. Direct overlap with Curida in nasal spray drug delivery, particularly as pharma customers often source both the device and the CDMO fill-finish service.

TypeBroad incumbent
Description

Global CDMO offering end-to-end pharmaceutical development and manufacturing services including sterile fill-finish and biologics. Comparable as a broad-based CDMO serving large pharma customers, though far larger and more diversified than Curida.

TypeBroad incumbent
Description

Swiss-based global CDMO with leading capabilities in biologics manufacturing (mammalian and microbial), as well as small-molecule fill-finish. Comparable to Curida Biologics in monoclonal antibody manufacturing and to the broader CDMO positioning.

TypeRegional player
Description

European contract development and manufacturing services arm of Eurofins Scientific, providing API development, biologics, and drug product services. Comparable to Curida in European CDMO positioning with biologics capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curida

Pharmaceutical Contract Manufacturingcurida.no

Curida is a Norwegian pharmaceutical CDMO specializing in Blow-Fill-Seal, nasal spray, and biologics contract manufacturing for pharmaceutical, biotech, and diagnostic clients across Europe and 80+ countries. It operates three GMP-certified sites delivering fill-finish, tech transfer, and commercial supply services.

What Curida does

Curida AS is a Norway-based pharmaceutical contract development and manufacturing organization (CDMO) specializing in sterile and non-sterile liquid formulations, with core competence in Blow-Fill-Seal (BFS) and nasal spray manufacturing. The company operates three GMP-certified sites in Norway — Elverum (the flagship BFS and nasal spray facility with 6 BFS lines and 4 nasal spray lines producing ~255 million units annually), Fornebu (biologics centre of excellence for monoclonal antibody manufacturing, formerly Diatec), and Ås (small-scale pharmacy formulations, cosmetics and nutrition, formerly Ås Produksjonslab). Founded in 2015 from a 1974-vintage Elverum plant revived by employees, Curida has grown via the 2017 Ås Produksjonslab acquisition and 2019 Diatec Monoclonals acquisition, consolidating three legacy business units under a unified CDMO brand in September 2025.

Curida sells end-to-end CDMO services — formulation, technology transfer (200+ SKUs completed to date under ISPE Good Practice Guide/PMI methodology), fill-finish across BFS, nasal spray, and liquid bottles (glass, LDPE, PET), controlled-drugs manufacturing (including morphine, fentanyl, and cannabis-based medicines), and analytical/microbiological testing — to pharmaceutical, biotech, and diagnostic customers across Europe and globally. The biologics franchise offers monoclonal antibody development, mammalian cell banking using 3L and 50L stirred-tank bioreactors, purification, and bioconjugation (10+ conjugation types) for IVD and clinical supply, serving 40+ diagnostic partners. In October 2025 the company announced a strategic partnership with Rommelag to install Europe's first BFS bottelpack 550 line, adding next-generation capacity and a sustainability-flexible platform to the sterile portfolio.

Curida's revenue model is B2B contract manufacturing services priced by project (formulation, tech transfer, fill-finish, commercial supply), with the customer base spanning academia and start-ups through to Big Pharma, and finished products exported to 80+ countries. Ownership is private and institutional: Signet Healthcare Partners (a US healthcare PE firm) led a 230M-260M NOK growth investment in April 2024 alongside existing Norwegian shareholders Canica, Investinor, Klaveness Marine, and Farvatn Private Equity. The company holds EU GMP, ISO 13485:2016, ISO 9001:2015 certifications, and in February 2026 earned an EcoVadis Bronze Award with a 17-point sustainability score improvement. Financial details, including revenue, are not publicly disclosed.

Curida firmographics

Firmographics
Name
Curida
Legal name
Curida AS
Website
https://curida.no
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Curida is a Norwegian pharmaceutical CDMO specializing in Blow-Fill-Seal, nasal spray, and biologics contract manufacturing for pharmaceutical, biotech, and diagnostic clients across Europe and 80+ countries. It operates three GMP-certified sites delivering fill-finish, tech transfer, and commercial supply services.
Ownership category
akta.pro rank

Curida industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Blow-fill-seal technology
  • Biologics manufacturing services
  • Nasal spray manufacturing
  • Sterile fill-finish

Where Curida is headquartered

Location

Headquarters

HQ city
Elverum
HQ country
Norway
HQ region
Europe

Offices4 records

Markets served

Curida business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Curida generates revenue through contract manufacturing services for pharmaceutical and biotech companies, providing end-to-end development and manufacturing of liquid pharmaceuticals, biologics, and diagnostic products. Services include formulation, tech transfer, fill-finish, and commercial scale-up under GMP conditions.
  2. Pharmacy Formulations Manufacturing: Small-scale manufacturing of pharmaceuticals, cosmetics, and nutrition products for Norwegian pharmacies and clients, including unlicensed pharmaceuticals and compounded products.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Curida product offering

Product offering

Core offering

Curida is a Norwegian pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and contract manufacturing of sterile and non-sterile liquid pharmaceuticals, biologics, and diagnostic products. The company specializes in Blow-Fill-Seal (BFS) and nasal spray manufacturing technologies, delivering services spanning formulation development, tech transfer, fill-finish, analytical testing, and commercial-scale GMP production from facilities in Elverum, Fornebu, and Ås, Norway.

Product overview

Curida is an integrated European CDMO offering end-to-end development and contract manufacturing of biologics and sterile or non-sterile liquid pharmaceuticals. The portfolio centers on three core service areas: Nasal & Ophthalmic Solutions (liquid formulations manufacturing using Blow-Fill-Seal and nasal spray technologies for uni-dose and multi-dose formats), Biologics & Diagnostic Solutions (monoclonal antibody development, manufacturing, and bioconjugation services), and Pharmacy Formulations (small-scale manufacturing for Norwegian pharmacies). Supporting these services are four technology platforms: Blow-Fill-Seal Technology, Nasal Spray Manufacturing, Liquid Bottles & Delivery Systems, and Uni-dose & Multi-dose Formats. A strategic partnership with Rommelag brings Europe's first BFS 550 bottelpack system. The company operates GMP-certified sites across Norway (Elverum, Fornebu, Ås) and serves pharmaceutical and diagnostic partners globally, exporting to over 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Curida Biologics: Biologics center of excellence at Technopolis, Fornebu, focusing on monoclonal antibody manufacturing for diagnostics and clinical supply.
  • Ås Produksjonslab

Products and services

  • Nasal & Ophthalmic Solutions
  • Biologics & Diagnostic Solutions
  • Pharmacy Formulations
  • Tech Transfer Services
  • Controlled Drugs Manufacturing
  • Bioconjugation Services
  • Analytical & Laboratory Services
  • Blow-Fill-Seal Manufacturing Technology
  • Nasal Spray Manufacturing Technology
  • Nasal Sprays & Suspensions

Quantifiable outcome

  • 200+ successful SKU tech transfers completed
  • +3 more outcomes

Companies that use Curida

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Curida technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Curida partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • AFRYminorImplementation/ SI/ Consulting Partner · 1 February 2026Partnership with AFRY to modernize Curida's quality management systems. AFRY implemented a connected, digital eQMS that improves visibility, strengthens data integrity, and supports faster, more informed decision-making for scalable and agile quality foundation.
  • RommelagcoreTechnology or Integration · 1 October 2025Strategic partnership with Rommelag, the global leader in Blow-Fill-Seal technology. Curida will become the first company in Europe to install Rommelag's BFS bottelpack 550 system - a next-generation platform designed to deliver greater flexibility, higher output, and enhanced sustainability in sterile liquid manufacturing. The partnership strengthens Curida's position as a European CDMO leader in Nasal & Ophthalmic solutions.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Curida competitors and assessment

Company assessment

Direct peers

  • Unither Pharmaceuticals: French-headquartered CDMO specializing in Blow-Fill-Seal sterile single-dose liquid manufacturing for ophthalmic, nasal, and respiratory applications. Most direct comparable to Curida in BFS technology focus, end markets, and customer profile.
  • Recipharm (Kindeva): European CDMO with significant sterile fill-finish and Blow-Fill-Seal capabilities serving pharma and biotech customers. Comparable to Curida in CDMO services, geographic base in Europe, and focus on liquid and semi-solid dosage forms.
  • Kindeva Drug Delivery: Former 3M Drug Delivery Systems business, now an independent CDMO specializing in inhalation, transdermal, and Blow-Fill-Seal manufacturing. Closely comparable to Curida in BFS expertise and pharmaceutical drug-delivery focus.
  • Aptar Pharma: Global leader in drug delivery systems including nasal spray pumps, closures, and dispensing components. Direct overlap with Curida in nasal spray drug delivery, particularly as pharma customers often source both the device and the CDMO fill-finish service.

Broad incumbents

  • Catalent: Large global CDMO offering sterile fill-finish, nasal spray, and biologics manufacturing across a broad portfolio. While much larger and broader in scope, Catalent overlaps directly with Curida in nasal spray and aseptic fill-finish CDMO services.
  • Aenova Group: European-headquartered CDMO with capabilities in solid, semi-solid, and liquid dosage forms including sterile manufacturing. Comparable to Curida as a European CDMO serving pharma customers with contract manufacturing services.
  • Vetter Pharma: German-headquartered CDMO specializing in sterile aseptic fill-finish of injectables and other complex liquid formulations. Comparable to Curida in sterile fill-finish focus, European base, and GMP-certified pharma CDMO positioning.
  • Thermo Fisher Scientific (Patheon): Global CDMO offering end-to-end pharmaceutical development and manufacturing services including sterile fill-finish and biologics. Comparable as a broad-based CDMO serving large pharma customers, though far larger and more diversified than Curida.
  • Lonza: Swiss-based global CDMO with leading capabilities in biologics manufacturing (mammalian and microbial), as well as small-molecule fill-finish. Comparable to Curida Biologics in monoclonal antibody manufacturing and to the broader CDMO positioning.

Regional players

  • Eurofins CDMO: European contract development and manufacturing services arm of Eurofins Scientific, providing API development, biologics, and drug product services. Comparable to Curida in European CDMO positioning with biologics capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Curida social profiles

Digital presence

Curida compliance and trust

Trust signal

Compliance6 records

Curida financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curida leadership team

Management profile

Number of profiles

Profiles14 records

Curida subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Curida funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curida M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curida

What does Curida do?

Curida is a Norwegian pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end development and contract manufacturing of sterile and non-sterile liquid pharmaceuticals, biologics, and diagnostic products. The company specializes in Blow-Fill-Seal (BFS) and nasal spray manufacturing technologies, delivering services spanning formulation development, tech transfer, fill-finish, analytical testing, and commercial-scale GMP production from facilities in Elverum, Fornebu, and Ås, Norway.

Is Curida a public or private company?

Curida is a private company. It is classified as private equity controlled and is currently operating.

When was Curida founded?

Curida was founded in 2015. It employs 51 to 100 people.

Where is Curida based?

Curida is headquartered in Elverum, Norway, in the Europe region.

How does Curida make money?

Two revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are pharmacy Formulations Manufacturing.

Who are Curida's main competitors?

Direct peers on record are Unither Pharmaceuticals, Recipharm (Kindeva), Kindeva Drug Delivery and Aptar Pharma. Broad incumbents are Catalent, Aenova Group, Vetter Pharma, Thermo Fisher Scientific (Patheon) and Lonza. Eurofins CDMO is listed as a regional player.

Does Curida have an API?

No public API is recorded for Curida.

What industry is Curida in?

Curida's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals